Targeted gene modification by parvoviral vectors

• US 8,846,387 B2
• Filed: 05/24/2011
• Issued: 09/30/2014
• Est. Priority Date: 04/24/1997
• Status: Expired due to Fees

• Current Assignee: University of Washington
• Original Assignee: University of Washington
• Inventors: Russell, David W., Hirata, Roli K.
• Primary Examiner(s): Nguyen, Quang
• Application Number:
  US13/114,117
• Publication Number:
  US 20120070890A1
• Time in Patent Office: 1,225 Days
• Field of Search: 435/320.1, 435/463, 424/93.2
• US Class Current: 435/320.1
• CPC Class Codes: C12N 15/86 Viral vectors
• CPC Class Codes: C12N 2750/14143 viral genome or elements thereof as genetic vector

Abstract

This invention provides methods for obtaining targeted gene modification in vertebrate cells using parvoviral vectors, including adeno-associated virus (AAV). The parvoviral vectors used in the methods of the invention are capable of targeting a specific genetic modification to a preselected target locus in a cellular genome by homologous pairing.

Claims

1. A recombinant, replication-defective adeno-associated virus (AAV) viral particle for introducing a genetic modification of a preselected target gene in the genome of a vertebrate cell by homologous recombination, the recombinant, replication-defective AAV viral particle comprising:

a targeting construct comprising a genomic DNA sequence which is substantially identical to the preselected target gene sequence except for the modification to be introduced;

wherein the genomic DNA sequence consists of less than an entire copy of the preselected target gene;

wherein the modification to be introduced is flanked by two regions of nucleotide sequence which are substantially identical to the preselected target gene sequence, each region being at least 100 nucleotides in length;

wherein the targeting construct comprises two AAV inverted terminal repeats (ITRs), one at each end of the targeting construct;

wherein the modification comprises one or more insertions or substitutions or a combination thereof; and

wherein the viral particle introduces the modification into the preselected target gene by homologous recombination at a frequency of at least 0.01%.

2. The recombinant viral particle of claim 1, wherein the preselected target gene sequence comprises a DNA sequence selected from the group consisting of a transcriptional regulatory region, a splice signal, a sequence involved in DNA replication, a matrix attachment point, a chromosomal recombination hotspot, a structural gene, or a coding region for a signal sequence, and portions thereof.

3. The recombinant viral particle of claim 2, wherein the DNA sequence comprises a structural gene and the modification results in an amino acid substitution, insertion, or a combination thereof, in a polypeptide encoded by the gene.

4. The recombinant viral particle of claim 2, wherein the DNA sequence comprises a transcriptional regulatory region selected from the group consisting of a promoter, an enhancer, a response element, a transcription termination signal, and a locus control region.

5. The recombinant viral particle of claim 4, wherein a gene under the control of the modified transcriptional regulatory region is expressed at a different level than that at which the gene is expressed under equivalent conditions when the gene is under the control of the unmodified transcriptional regulatory region.

6. The recombinant viral particle of claim 1 wherein the targeting construct includes a recombination signal that is flanked by the nucleotide sequences that are substantially identical to the preselected target gene.

7. The recombinant viral particle of claim 6 wherein the recombination signal is one or more Lox sites.

8. The recombinant viral particle of claim 1 wherein the targeting construct further comprises a selectable marker.

9. The recombinant viral particle of claim 8 wherein the selectable marker comprises the neo gene or hyg gene.

10. The recombinant viral particle of claim 1 wherein the targeting construct further comprises a screenable marker.

11. The recombinant viral particle of claim 10 wherein the screenable marker comprises a gene encoding β

-galactosidase, β

-glucuronidase, luciferase, alkaline phosphatase or a fluorescent maker.

12. The recombinant viral particle of claim 1 wherein the targeting construct further comprises a targeting enhancer.

13. The recombinant viral particle of claim 1 wherein the AAV rep and cap genes have been deleted.

14. The recombinant viral particle of claim 1 comprising two targeting constructs.

15. The recombinant viral particle of claim 1 , comprising a capsid having one or more modifications to improve cell targeting.

16. The recombinant viral particle of claim 1 wherein the viral particle consists essentially of particles comprising either all plus or all minus strands.

17. The recombinant viral particle of claim 1 wherein the targeting construct further comprises a DNA that is exogenous to the vertebrate cell, wherein the exogenous DNA is preselected for modification of the genomic target locus.

18. The recombinant viral particle of claim 17, wherein the exogenous DNA comprises a selection marker that is functional in the vertebrate cell.

19. The recombinant viral particle of claim 1, wherein the viral particle introduces the modification into the preselected target gene by homologous recombination at a frequency of at least 0.1%.

20. The recombinant viral particle of claim 1, wherein the viral particle introduces the modification into the preselected target gene by homologous recombination at a frequency of at least 1%.